Every issue of the magazine is mailed directly to those whose profession makes them responsible for the health, well-being and treatment of horses every day. Horse Health's core readership is made up of the industry's decision-makers - the people with significant buying power at riding schools, livery yards, training schools, bloodstock agencies, veterinary practices, breeders and competition yards.
WORLD Horse Welfare has launched a new campaign to get people talking about the practical arrangements of having their horse put to sleep.
The aim is to encourage people to make a plan for that final decision well in advance, as currently the subject is rarely discussed openly and can lead to major welfare problems.
Samantha Lewis, manager of the Just in Case initiative, said: 'The idea is to get people talking about the difficult subject of having their horse put to sleep."
Pathophysiology and Nutritional Management of Pituitary Pars Intermedia Dysfunction – Cushing’s Syndrome
By Catherine Hale, Product and Nutrition Manager for Allen & Page and Company Nutritionist Claire Lawrence
Carson NR. (2003) Physiology of Behaviour, Pearson Education
DeMaria JE, Lerant AA and Freeman ME. (1999) Prolactin activates all three populations of hypothalamic neuroendocrine dopaminergic neurons in ovariectomized rats. Brain Res. 837 pp.236-241.
Geor R (2010). Digestive strategy and flexibility in horses with reference to dietary carbohydrates. In: the impact of nutrition on health and welfare of horses, EAAP 128.
Grenager N (2010) How does Cushing’s Disease relate to laminitis? Advances in diagnosis and treatment. J Eq Vet Sci, 30 (9) pp.482-490.
Glover CM, Miller LM, Dybdal NO, Lopez A, Duckett WM and McFarlane D (2009) Extrapituitary and pituitary pathological findings in horses with pituitary pars intermedia dysfunction: A retrospective study. 29 (3) pp.146-153.
Lee Z-Y, Zylstra R and Haritou SJA (2010) The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses. The Vet J, 185 pp.58-61.
McFarlane D., Cribb AE. (2005) Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses. Am J Vet Res, 66 pp.2065-2072.
McFarlane D., Donaldson MT, Saleh TM and Cribb AE. (2003) The role of dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction (equine Cushing’s disease). In: Proceedings of the 49th Annual Convention of the American Association of Equine Practitioners, New Orleans, USA. pp.233-237.
Orth DN and Nicholson WE. (1982) Bioactive and immunoactive adrenocorticotrophin in normal equine pituitary and pituitary tumors of horse’s with Cushing’s disease. Endocrinology, 111 pp.559-563.
Schott HC. (2002) Pituitary pars intermedia dysfunction: equine Cushing’s disease. Vet Clin North Am, 18 pp.237-270.
Saland LC. (2001) The mammalian pituitary intermediate lobe: an update on innervations and regulation. Brain Res Bull, 54 pp.587-593.
Treiber KH, Kronfeld DS, Hess TM, Byrd BM, Splan RK and Staniar WB. (2006). Evaluation of genetic and metabolic predispositions and nutritional risk factors for pasture-associated laminitis in ponies. J Am Vet Med Assoc, 228. pp.1538-1545.
Wilson MG, Nicholson WE, Holscher MA, Sherrell BJ, Mount CD and Orth DN. (1982) Pro-opiolipomelanocortin peptides in normal pituitary, pituitary tumor and plasma of normal and Cushing’s horses. Endocrinology, 110. pp.941-954.
